{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:51:23Z","timestamp":1790704283397,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hand-foot syndrome (HFS) significantly impacts quality of life in cancer patients undergoing capecitabine treatment. This study assessed capecitabine-associated HFS prevalence, its impacts on chemotherapy treatment, and identified risk factors in multiracial Malaysian patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included adult cancer patients receiving capecitabine at Sarawak General Hospital for at least two cycles from April 1, 2021 to June 30, 2022. HFS rates, time to HFS, and proportions of HFS-related treatment modifications were determined. Characteristics between patients with and without HFS were compared and multivariable logistic regression was used to identify risk factors for all-grade HFS and grade \u22652.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 369 patients, 185 (50.1%) developed HFS, with 14.6% experiencing grade \u22652 and 21.6% (40\/185) underwent treatment modifications. Risk factors for all-grade HFS include older age (OR 1.03 95%CI 1.01, 1.06), prior chemotherapy (OR 2.09 95%CI 1.22, 3.58), higher capecitabine dose (OR 2.96 95%CI 1.62, 5.38), prolonged treatment (OR 1.36 95%CI 1.21, 1.51), folic acid intake (OR 3.27 95%CI 1.45, 7.35) and lower neutrophil count (OR 0.77 95%CI 0.66, 0.89). For HFS grade \u22652, older age (OR 1.04 95%CI 1.01, 1.08), female sex (OR 2.10 95%CI 1.05, 4.18), Chinese race (OR 2.10 95%CI 1.06, 4.18), and higher capecitabine dose (OR 2.62 95%CI 1.28, 5.35) are significant risk factors. Use of calcium channel blockers were associated with reduced risks of all-grade HFS\u00a0(OR 0.27, 95%CI 0.12, 0.60) and grade \u22652\u00a0(OR 0.21 95%CI 0.06, 0.78).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides real-world data on capecitabine-induced HFS in Malaysian patients and identifies risk factors that may offer insights into its understanding and management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-024-08490-7","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:17:00Z","timestamp":1715645820000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2563-7369","authenticated-orcid":false,"given":"Teck Long","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-9860","authenticated-orcid":false,"given":"Pei Jye","family":"Voon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-7629","authenticated-orcid":false,"given":"Kah Hay","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0161-8203","authenticated-orcid":false,"given":"Dzul Azri","family":"Mohamed Noor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"2","key":"8490_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12156-011-0074-3","volume":"5","author":"L Chintala","year":"2011","unstructured":"Chintala L, Vaka S, Baranda J, Williamson SK (2011) Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now? Oncol Rev 5(2):129\u2013140. https:\/\/doi.org\/10.1007\/s12156-011-0074-3","journal-title":"Oncol Rev"},{"issue":"1","key":"8490_CR2","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1038\/s41598-017-07750-3","volume":"7","author":"E Ter Veer","year":"2017","unstructured":"Ter Veer E, Ngai LL, Valkenhoef GV, Mohammad NH, Anderegg MCJ, van Oijen MGH, van Laarhoven HWM (2017) Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis. Sci Rep 7(1):7142. https:\/\/doi.org\/10.1038\/s41598-017-07750-3","journal-title":"Sci Rep"},{"issue":"1","key":"8490_CR3","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4081\/oncol.2020.442","volume":"14","author":"JJM Kwakman","year":"2020","unstructured":"Kwakman JJM, Elshot YS, Punt CJA, Koopman M (2020) Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev 14(1):442. https:\/\/doi.org\/10.4081\/oncol.2020.442","journal-title":"Oncol Rev"},{"issue":"3","key":"8490_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1078155206069242","volume":"12","author":"SM Gressett","year":"2006","unstructured":"Gressett SM, Stanford BL, Hardwicke F (2006) Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 12(3):131\u2013141. https:\/\/doi.org\/10.1177\/1078155206069242","journal-title":"J Oncol Pharm Pract"},{"key":"8490_CR5","unstructured":"U.S. Department of Health and Human Services (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. United States. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 12 February 2024"},{"key":"8490_CR6","doi-asserted-by":"publisher","first-page":"101670","DOI":"10.1016\/j.ejon.2019.09.011","volume":"43","author":"YH Hsu","year":"2019","unstructured":"Hsu YH, Shen WC, Wang CH, Lin YF, Chen SC (2019) Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy. Eur J Oncol Nurs 43:101670. https:\/\/doi.org\/10.1016\/j.ejon.2019.09.011","journal-title":"Eur J Oncol Nurs"},{"issue":"20","key":"8490_CR7","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.7150\/jca.31059","volume":"10","author":"R Urakawa","year":"2019","unstructured":"Urakawa R, Tarutani M, Kubota K, Uejima E (2019) Hand Foot Syndrome Has the Strongest Impact on QOL in Skin Toxicities of Chemotherapy. J Cancer 10(20):4846\u20134851. https:\/\/doi.org\/10.7150\/jca.31059","journal-title":"J Cancer"},{"key":"8490_CR8","unstructured":"Genetech USA (2015) XELODA (capecitabine) tablets, for oral use: Highlights for prescribing information. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020896s037lbl.pdf. Accessed 31 October 2023"},{"issue":"1","key":"8490_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40268-016-0154-8","volume":"17","author":"LW Leicher","year":"2017","unstructured":"Leicher LW, de Graaf JC, Coers W, Tascilar M, de Groot JW (2017) Tolerability of capecitabine monotherapy in metastatic colorectal cancer: a real-world study. Drugs R D 17(1):117\u2013124. https:\/\/doi.org\/10.1007\/s40268-016-0154-8","journal-title":"Drugs R D"},{"issue":"3","key":"8490_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10549-012-2288-x","volume":"136","author":"JL Blum","year":"2012","unstructured":"Blum JL, Barrios CH, Feldman N, Verma S, McKenna EF, Lee LF, Scotto N, Gralow J (2012) Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 136(3):777\u2013788. https:\/\/doi.org\/10.1007\/s10549-012-2288-x","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"8490_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00384-023-04345-5","volume":"38","author":"J Huang","year":"2023","unstructured":"Huang J, Ye S, Feng S, Zheng M, Zhong M (2023) Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 38(1):61. https:\/\/doi.org\/10.1007\/s00384-023-04345-5","journal-title":"Int J Colorectal Dis"},{"key":"8490_CR12","volume-title":"MOH Mulls Building New Cancer Centre In Samarahan","author":"CodeBlue","year":"2021","unstructured":"CodeBlue (2021) MOH Mulls Building New Cancer Centre In Samarahan. CodeBlue. Available from:, Malaysia https:\/\/codeblue.galencentre.org\/2021\/11\/17\/moh-mulls-building-new-cancer-centre-in-samarahan. Accessed 31 May 2023"},{"key":"8490_CR13","volume-title":"Cancer Drug Counselling: A Guide for Pharmacists","author":"N Mohamad","year":"2017","unstructured":"Mohamad N, Othman NA, Yusup NL (2017) Cancer Drug Counselling: A Guide for Pharmacists. Pharmaceutical Services Division, Ministry of Health Malaysia, Malaysia Available from: https:\/\/pharmacy.moh.gov.my\/sites\/default\/files\/document-upload\/cancer-drug-counselling-guide-pharmacists-2016.pdf. Accessed 18 March 2024"},{"issue":"1","key":"8490_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"issue":"22","key":"8490_CR15","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1200\/JCO.2014.60.4587","volume":"33","author":"RD Hofheinz","year":"2015","unstructured":"Hofheinz RD, Gencer D, Schulz H, Stahl M, Hegewisch-Becker S, Loeffler LM, Kronawitter U, Bolz G, Potenberg J et al (2015) Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group. J Clin Oncol 33(22):2444\u20132449. https:\/\/doi.org\/10.1200\/JCO.2014.60.4587","journal-title":"J Clin Oncol"},{"issue":"35","key":"8490_CR16","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1200\/JCO.2010.31.1431","volume":"28","author":"SL Wolf","year":"2010","unstructured":"Wolf SL, Qin R, Menon SP, Rowland KM Jr, Thomas S, Delaune R, Christian D, Pajon ER Jr, Satele DV et al (2010) Placebo-controlled trial to determine the effectiveness of a urea\/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 28(35):5182\u20135187. https:\/\/doi.org\/10.1200\/JCO.2010.31.1431","journal-title":"J Clin Oncol"},{"issue":"4","key":"8490_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/bjc.2012.318","volume":"107","author":"PG Corrie","year":"2012","unstructured":"Corrie PG, Bulusu R, Wilson CB, Armstrong G, Bond S, Hardy R, Lao-Sirieix S, Parashar D, Ahmad A et al (2012) A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. Br J Cancer 107(4):585\u2013587. https:\/\/doi.org\/10.1038\/bjc.2012.318","journal-title":"Br J Cancer"},{"issue":"5","key":"8490_CR18","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/annonc\/mdr400","volume":"23","author":"RX Zhang","year":"2012","unstructured":"Zhang RX, Wu XJ, Wan DS, Lu ZH, Kong LH, Pan ZZ, Chen G (2012) Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23(5):1348\u20131353. https:\/\/doi.org\/10.1093\/annonc\/mdr400","journal-title":"Ann Oncol"},{"issue":"6","key":"8490_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1159\/000322660","volume":"5","author":"D Yamamoto","year":"2010","unstructured":"Yamamoto D, Yamamoto C, Iwase S, Kuroda Y, Odagiri H, Nagumo Y (2010) Efficacy of Vitamin E Treatment for Hand-Foot Syndrome in Patients Receiving Capecitabine. Breast Care (Basel) 5(6):415\u2013416. https:\/\/doi.org\/10.1159\/000322660","journal-title":"Breast Care (Basel)"},{"key":"8490_CR20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12885-016-2113-8","volume":"16","author":"A Stein","year":"2016","unstructured":"Stein A, Quidde J, Schroder JK, Gohler T, Tschechne B, Valdix AR, Hoffkes HG, Schirrmacher-Memmel S, Wohlfarth T et al (2016) Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study. BMC Cancer 16:82. https:\/\/doi.org\/10.1186\/s12885-016-2113-8","journal-title":"BMC Cancer"},{"issue":"2","key":"8490_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ygyno.2009.04.007","volume":"114","author":"JL Tanyi","year":"2009","unstructured":"Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK (2009) Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer. Gynecol Oncol 114(2):219\u2013224. https:\/\/doi.org\/10.1016\/j.ygyno.2009.04.007","journal-title":"Gynecol Oncol"},{"issue":"1","key":"8490_CR22","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1186\/s12885-022-10026-3","volume":"22","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Mason M, Cho Y, Chittiprolu A, Zhang X, Harden K, Gong Y, Harris MR, Barton DL (2022) Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes. BMC Cancer 22(1):950. https:\/\/doi.org\/10.1186\/s12885-022-10026-3","journal-title":"BMC Cancer"},{"key":"8490_CR23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ejca.2015.10.013","volume":"54","author":"D Meulendijks","year":"2016","unstructured":"Meulendijks D, van Hasselt JGC, Huitema ADR, van Tinteren H, Deenen MJ, Beijnen JH, Cats A, Schellens JHM (2016) Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. Eur J Cancer 54:120\u2013130. https:\/\/doi.org\/10.1016\/j.ejca.2015.10.013","journal-title":"Eur J Cancer"},{"issue":"3","key":"8490_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s40801-018-0138-9","volume":"5","author":"MWH van Beek","year":"2018","unstructured":"van Beek MWH, Roukens M, Jacobs WCH, Timmer-Bonte JNH, Kramers C (2018) Real-World Adverse Effects of Capecitabine Toxicity in an Elderly Population. Drugs Real World Outcomes 5(3):161\u2013167. https:\/\/doi.org\/10.1007\/s40801-018-0138-9","journal-title":"Drugs Real World Outcomes"},{"issue":"7","key":"8490_CR25","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/bjc.2013.517","volume":"109","author":"SG Louie","year":"2013","unstructured":"Louie SG, Ely B, Lenz HJ, Albain KS, Gotay C, Coleman D, Raghavan D, Shields AF, Gold PJ et al (2013) Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). Br J Cancer 109(7):1744\u20131749. https:\/\/doi.org\/10.1038\/bjc.2013.517","journal-title":"Br J Cancer"},{"issue":"3","key":"8490_CR26","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1177\/1078155215587345","volume":"22","author":"AI Ilich","year":"2016","unstructured":"Ilich AI, Danilak M, Kim CA, Mulder KE, Spratlin JL, Ghosh S, Chambers CR, Sawyer MB (2016) Effects of gender on capecitabine toxicity in colorectal cancer. J Oncol Pharm Pract 22(3):454\u2013460. https:\/\/doi.org\/10.1177\/1078155215587345","journal-title":"J Oncol Pharm Pract"},{"key":"8490_CR27","doi-asserted-by":"publisher","unstructured":"Ozdemir BC, Gerard CL, Espinosa da Silva C (2022) Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology. Endocrinology 163(6). https:\/\/doi.org\/10.1210\/endocr\/bqac058","DOI":"10.1210\/endocr\/bqac058"},{"issue":"5","key":"8490_CR28","doi-asserted-by":"publisher","first-page":"e000770","DOI":"10.1136\/esmoopen-2020-000770","volume":"5","author":"AD Wagner","year":"2020","unstructured":"Wagner AD (2020) Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy. ESMO Open 5(5):e000770. https:\/\/doi.org\/10.1136\/esmoopen-2020-000770","journal-title":"ESMO Open"},{"issue":"2","key":"8490_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.annonc.2021.11.011","volume":"33","author":"BC Ozdemir","year":"2022","unstructured":"Ozdemir BC, Oertelt-Prigione S, Adjei AA, Borchmann S, Haanen JB, Letsch A, Mir O, Quaas A, Verhoeven RHA et al (2022) Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force. Ann Oncol 33(2):126\u2013128. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.011","journal-title":"Ann Oncol"},{"issue":"2","key":"8490_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.20524\/aog.2022.0688","volume":"35","author":"A Brazelton","year":"2022","unstructured":"Brazelton A, Yande S, Pope R, Johnson ML, Musher B, Trivedi MV (2022) Racial and ethnic differences in capecitabine toxicity in patients with gastrointestinal tract cancers. Ann Gastroenterol 35(2):182\u2013186. https:\/\/doi.org\/10.20524\/aog.2022.0688","journal-title":"Ann Gastroenterol"},{"issue":"17","key":"8490_CR31","doi-asserted-by":"publisher","first-page":"18098","DOI":"10.1002\/cam4.6370","volume":"12","author":"J Mizusawa","year":"2023","unstructured":"Mizusawa J, Sato H, Rubinstein LV, Fujiwara T, Yonemori K, Hirakawa A (2023) Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials. Cancer Med 12(17):18098\u201318109. https:\/\/doi.org\/10.1002\/cam4.6370","journal-title":"Cancer Med"},{"issue":"10","key":"8490_CR32","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2013.51.1857","volume":"32","author":"D Rosmarin","year":"2014","unstructured":"Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P et al (2014) Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 32(10):1031\u20131039. https:\/\/doi.org\/10.1200\/JCO.2013.51.1857","journal-title":"J Clin Oncol"},{"issue":"1","key":"8490_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40880-019-0399-z","volume":"39","author":"S Lin","year":"2019","unstructured":"Lin S, Yue J, Guan X, Yuan P, Wang J, Luo Y, Fan Y, Cai R, Li Q et al (2019) Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer. Cancer Commun (Lond) 39(1):57. https:\/\/doi.org\/10.1186\/s40880-019-0399-z","journal-title":"Cancer Commun (Lond)"},{"issue":"3","key":"8490_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2710.2011.01289.x","volume":"37","author":"Y Ma","year":"2012","unstructured":"Ma Y, Tang L, Wang HX, Xu YC, Ma Y, Zhang FC (2012) Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity. J Clin Pharm Ther 37(3):266\u2013275. https:\/\/doi.org\/10.1111\/j.1365-2710.2011.01289.x","journal-title":"J Clin Pharm Ther"},{"issue":"11","key":"8490_CR35","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1001\/jamaoncol.2017.1269","volume":"3","author":"YS Yap","year":"2017","unstructured":"Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA et al (2017) Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial. JAMA Oncol 3(11):1538\u20131545. https:\/\/doi.org\/10.1001\/jamaoncol.2017.1269","journal-title":"JAMA Oncol"},{"issue":"21","key":"8490_CR36","doi-asserted-by":"publisher","first-page":"9225","DOI":"10.7314\/apjcp.2014.15.21.9225","volume":"15","author":"AK Zahrina","year":"2014","unstructured":"Zahrina AK, Norsa'adah B, Hassan NB, Norazwany Y, Norhayati I, Roslan MH, Wan Nazuha WR (2014) Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia. Asian Pac J Cancer Prev 15(21):9225\u20139232. https:\/\/doi.org\/10.7314\/apjcp.2014.15.21.9225","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"8490_CR37","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ajcnut.2023.11.023","volume":"119","author":"DE Kok","year":"2024","unstructured":"Kok DE, van Duijnhoven FJ, Lubberman FJ, McKay JA, Lanen AV, Winkels RM, Wesselink E, van Halteren HK, de Wilt JH et al (2024) Intake and biomarkers of folate and folic acid as determinants of chemotherapy-induced toxicities in patients with colorectal cancer: a cohort study. Am J Clin Nutr 119(2):294\u2013301. https:\/\/doi.org\/10.1016\/j.ajcnut.2023.11.023","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"8490_CR38","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3(5):330\u2013338. https:\/\/doi.org\/10.1038\/nrc1074","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"8490_CR39","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/ced.14486","volume":"46","author":"S Lian","year":"2021","unstructured":"Lian S, Zhang X, Zhang Y, Zhao Q (2021) Pyridoxine for prevention of hand\u2013foot syndrome caused by chemotherapy agents: a meta-analysis. Clin Exp Dermatol 46(4):629\u2013635. https:\/\/doi.org\/10.1111\/ced.14486","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"8490_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1161\/CIRCRESAHA.109.200311","volume":"105","author":"R Das","year":"2009","unstructured":"Das R, Burke T, Van Wagoner DR, Plow EF (2009) L-type calcium channel blockers exert an antiinflammatory effect by suppressing expression of plasminogen receptors on macrophages. Circ Res 105(2):167\u2013175. https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.200311","journal-title":"Circ Res"},{"issue":"1","key":"8490_CR41","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/ajh.2007.13","volume":"21","author":"E Shima","year":"2008","unstructured":"Shima E, Katsube M, Kato T, Kitagawa M, Hato F, Hino M, Takahashi T, Fujita H, Kitagawa S (2008) Calcium channel blockers suppress cytokine-induced activation of human neutrophils. Am J Hypertens 21(1):78\u201384. https:\/\/doi.org\/10.1038\/ajh.2007.13","journal-title":"Am J Hypertens"},{"issue":"7","key":"8490_CR42","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000529851","volume":"101","author":"Y Kanbayashi","year":"2023","unstructured":"Kanbayashi Y, Taguchi T, Ishikawa T, Otsuji E, Takayama K (2023) Risk factors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study. Oncology 101(7):407\u2013414. https:\/\/doi.org\/10.1159\/000529851","journal-title":"Oncology"},{"issue":"5","key":"8490_CR43","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.21873\/anticanres.15737","volume":"42","author":"M Takemura","year":"2022","unstructured":"Takemura M, Ikemura K, Yoshinami T, Toyozumi Y, Shintani T, Ueda M, Shimazu K, Okuda M (2022) Proton pump inhibitors ameliorate capecitabine-induced hand-foot syndrome in patients with breast cancer: a retrospective study. Anticancer Res 42(5):2591\u20132598. https:\/\/doi.org\/10.21873\/anticanres.15737","journal-title":"Anticancer Res"},{"issue":"6","key":"8490_CR44","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamaoncol.2016.3358","volume":"3","author":"MP Chu","year":"2017","unstructured":"Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K et al (2017) association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013\/LOGiC randomized clinical trial. JAMA Oncol 3(6):767\u2013773. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3358","journal-title":"JAMA Oncol"},{"issue":"3","key":"8490_CR45","doi-asserted-by":"publisher","first-page":"e000347","DOI":"10.1136\/esmoopen-2018-000347","volume":"3","author":"A Grothey","year":"2018","unstructured":"Grothey A, Yoshino T, Bodoky G, Ciuleanu T, Garcia-Carbonero R, Garcia-Alfonso P, Van Cutsem E, Muro K, Mytelka DS et al (2018) Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. ESMO Open 3(3):e000347. https:\/\/doi.org\/10.1136\/esmoopen-2018-000347","journal-title":"ESMO Open"},{"issue":"2","key":"8490_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/bjc.2015.419","volume":"114","author":"C Zielinski","year":"2016","unstructured":"Zielinski C, Lang I, Beslija S, Kahan Z, Inbar MJ, Stemmer SM, Anghel R, Vrbanec D, Messinger D et al (2016) Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. Br J Cancer 114(2):163\u2013170. https:\/\/doi.org\/10.1038\/bjc.2015.419","journal-title":"Br J Cancer"},{"issue":"10","key":"8490_CR47","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1021\/acs.chemrestox.6b00215","volume":"29","author":"Y Lou","year":"2016","unstructured":"Lou Y, Wang Q, Zheng J, Hu H, Liu L, Hong D, Zeng S (2016) Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome. Chem Res Toxicol 29(10):1591\u20131601. https:\/\/doi.org\/10.1021\/acs.chemrestox.6b00215","journal-title":"Chem Res Toxicol"},{"key":"8490_CR48","volume-title":"Malaysian Guideline for Good Clinical Practice","author":"Subcommittee of Malaysian Guidelines for Good Clinical Practice","year":"2018","unstructured":"Subcommittee of Malaysian Guidelines for Good Clinical Practice (2018) Malaysian Guideline for Good Clinical Practice. National Pharmaceutical Regulatory Agency, Malaysia Available from: http:\/\/www.nccr.gov.my\/view_file.cfm?fileid=31. Accessed 31 May 2023"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08490-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08490-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08490-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T08:07:02Z","timestamp":1718611622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08490-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["8490"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08490-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3708128\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol received approval from Medical Research and Ethics Committee of the Ministry of Health, Malaysia (NMRR ID-22-01737-RYT). The study was conducted in compliance with Malaysian Guideline for Good Clinical Practice [\n                      \n                      ] and Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic approval"}},{"value":"Given the retrospective nature of this study, the informed consent process was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"345"}}